AYTU BIOPHARMA, INC. Key Metrics

2 years of history · ending 2025-06-30 · SEC EDGAR

Forensics

Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.

F-Score (Piotroski 0-9)

Turnover & Efficiency Analysis (days)

Expense Ratios

Working Capital Analysis

52-Week Range

Trailing Returns

ROIC vs WACC

Liquidity & Leverage Ratios

Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)

EPS (Diluted)
Book Value Per Share
Free Cash Flow Per Share
Cash Per Share
Revenue Per Share
OCF Per Share
Return on Equity
-58.1%
Return on Assets
-11.2%
Return on Invested Capital
-18.1%
Debt to Equity
0.57
Current Ratio
1.26
Quick Ratio
1.07
Asset Turnover
0.55
Days Sales Outstanding
171.31
Days Payables Outstanding
188.28
Days Inventory On Hand
203.08
Cash Conversion Cycle
186.10
R&D / Revenue
2.0%
SBC / Revenue
0.9%
Capex / Revenue
0.3%
Working Capital
$16M
Net Current Asset Value
$79M
Invested Capital
$30M
OCF / Net Income
0.14
FCF / Net Income
0.16
Accruals Ratio (Sloan)
-9.4%
Net Debt
$-20M
Net Debt / EBITDA
2.63
Interest Coverage
-2.11
Cash Coverage
-0.52
Capex Coverage
-8.50
Tangible Common Equity
$-23M
TCE / Total Assets
-18.7%
Goodwill / Total Assets
NOPAT
$-6M
Cash ROIC
-6.3%
WC / Revenue
24.3%
Capex / D&A
1.14
Reinvestment Rate
-0.4%
Asset Growth vs Revenue Growth
3.3%
Revenue 5Y CAGR
19.2%
Book Value 5Y CAGR
-27.6%
Stock Price (FY-end)
$2
Market Cap
P/S Ratio
P/B Ratio
Enterprise Value
EV / Sales
FCF Yield
Shareholder Yield
R&D Yield
Capex Yield
Shares Variation (YoY)
Beta (5Y)
0.83
Cost of Equity
8.6%
Cost of Debt (after tax)
26.9%
WACC
ROIC - WACC Spread
52W High
$3
52W Low
$1
Trailing Return 1Y
-24.3%
Trailing Return 5Y
-99.3%
F-Score (Piotroski)
4.00
Z-Score (Altman)

Earnings Forecasts

Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).

Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.

EPS — Consensus vs Actual

Revenue — Consensus vs Actual

Stock Price on Earnings Dates

AYTU BIOPHARMA, INC. — Effective Tax Rate ReconciliationNEW

Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.

Effective Rate Trend

Reconciliation LineFY2020FY2021FY2022FY2023FY2024FY2025
Federal Statutory Rate21.00%21.00%21.00%21.00%
State & Local Income Taxes-5.71%-4.24%2.50%8.70%-0.20%
Foreign Rate Differential
Other Adjustments0.35%1.13%0.01%-0.70%-0.30%-6.00%
SBC (Nondeductible)-0.25%0.07%0.27%
Valuation Allowance Change25.02%24.96%11.31%-24.00%-49.80%-17.90%
Tax Law Change0.00%
Effective Tax Rate0.00%0.45%-0.09%0.00%-20.60%-3.20%

Cash vs Accrual

ItemFY2020FY2021FY2022FY2023FY2024FY2025
Income Tax Expense (Accrual)$259.0K−$110.0K$2.1M$437.0K
Income Taxes Paid (Cash)$1.6M$1.4M